Passage Bio Seeks Pennsylvania College Student Candidates for Third Annual Tachi Yamada Scholarship Program
March 05 2024 - 7:00AM
Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic
medicines company focused on improving the lives of patients with
neurodegenerative diseases, today announced the opening of its
application process for its third annual Tachi Yamada Scholarship
program.
The scholarship program is for junior students enrolled in life
science programs at four-year colleges and universities in
Pennsylvania and who plan to have a career in the life sciences
industry. Passage Bio will select one sophomore student annually to
award $10,000 in scholarship funding – $5,000 over two consecutive
years to be used toward college-related expenses. Interested
sophomore students have until April 26, 2024, to apply for the
scholarship.
Passage Bio first announced its plans to launch the annual Tachi
Yamada Scholarship Program in October 2021 to continue the legacy
of Tadataka (Tachi) Yamada, M.D., a visionary biopharma industry
leader who passed away in August 2021. A co-founder of Passage Bio
and chairman of the company's board of directors, Tachi
demonstrated a lifelong commitment to mentoring and fostering the
development of the upcoming generation of scientists.
“Entering its third year, the Tachi Yamada Scholarship program
stands as a proud testament to our ongoing dedication to nurturing
students who aspire to drive meaningful change through the realms
of science. Through this initiative, we pay homage to Tachi's
enduring legacy and his invaluable contributions to our field,"
said Will Chou, M.D., president and chief executive officer of
Passage Bio. “We look forward to welcoming and supporting the next
exceptional scholar who will undoubtedly make an impact in the life
sciences industry.”
In addition to the financial award, the selected scholar will be
matched with a Passage Bio mentor for professional growth
opportunities over the two-year scholarship period.
To apply, students must be sophomores, who will be juniors in
the fall of 2024, attending four-year colleges or universities in
Pennsylvania and majoring in a life science discipline. They must
have a cumulative unweighted grade point average of 3.0 and be a
United States citizen or permanent resident of the United States or
hold a U.S. student visa. The student must also write a 500-word
essay as part of the application process. The official rules and
application details are available on Passage Bio’s website in the
Careers section at Passage Bio, Inc. – Careers. Applications must
be submitted by April 26, 2024 and will be evaluated by a panel of
Passage Bio employees; the winner will be selected by Passage Bio
at its discretion.
About Passage Bio
Passage Bio (Nasdaq: PASG) is a clinical stage genetic medicines
company on a mission to improve the lives of patients with
neurodegenerative diseases. Our primary focus is the development
and advancement of cutting-edge, one-time therapies designed to
target the underlying pathology of these conditions. Passage Bio’s
lead product candidate, PBFT02, seeks to treat neurodegenerative
conditions, including frontotemporal dementia, by elevating
progranulin levels to restore lysosomal function and slow disease
progression.
To learn more about Passage Bio and our steadfast commitment to
protecting patients and families against loss in neurodegenerative
conditions, please visit: www.passagebio.com.
For further information, please contact:
Investors: Stuart Henderson Passage Bio
267.866.0114 shenderson@passagebio.com
Media:Mike BeyerSam Brown Inc. Healthcare
Communications312.961.2502MikeBeyer@sambrown.com
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Jul 2024 to Aug 2024
Passage Bio (NASDAQ:PASG)
Historical Stock Chart
From Aug 2023 to Aug 2024